Lead Product(s) : Delgocitinib
Therapeutic Area : Dermatology
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LEO Pharma Receives Positive CHMP Opinion for Anzupgo® in Hand Eczema Treatment
Details : Anzupgo (delgocitinib) cream is an investigational, first-in-class, topical pan-JAK inhibitor for CHE. It is under clinical development for the treatment of Moderate to Severe Chronic Hand Eczema.
Brand Name : Anzupgo
Molecule Type : Small molecule
Upfront Cash : Not Applicable
July 25, 2024
Lead Product(s) : Delgocitinib
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Delgocitinib
Therapeutic Area : Dermatology
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : LP0133 (delgocitinib) cream is an investigational, first-in-class, topical pan-Janus kinase (JAK) inhibitor for CHE. It is under phase 3 clinical development for the treatment of Moderate to Severe Chronic Hand Eczema.
Brand Name : LP0133
Molecule Type : Small molecule
Upfront Cash : Not Applicable
January 24, 2024
Lead Product(s) : Delgocitinib
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Delgocitinib
Therapeutic Area : Dermatology
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : LP0133 (delgocitinib) is a first-in-class investigational topical pan-Janus kinase (JAK)-inhibitor that inhibits activation of the JAK-STAT pathway, which plays a key role in the immune system in driving the pathophysiology of chronic inflammatory skin d...
Brand Name : LP0133
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 30, 2023
Lead Product(s) : Delgocitinib
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Delgocitinib
Therapeutic Area : Dermatology
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : LP0133 (delgocitinib) is a first-in-class investigational topical pan-Janus kinase (JAK)-inhibitor that inhibits activation of the JAK-STAT pathway, which plays a key role in the immune system in driving the pathophysiology of chronic inflammatory skin d...
Brand Name : LP0133
Molecule Type : Small molecule
Upfront Cash : Not Applicable
February 10, 2023
Lead Product(s) : Delgocitinib
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Delgocitinib
Therapeutic Area : Dermatology
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : LP0133 (delgocitinib) is a first-in-class investigational topical pan-Janus kinase (JAK)-inhibitor that inhibits activation of the JAK-STAT pathway, which plays a key role in the immune system in driving the pathophysiology of chronic inflammatory skin d...
Brand Name : LP0133
Molecule Type : Small molecule
Upfront Cash : Not Applicable
December 05, 2022
Lead Product(s) : Delgocitinib
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Delgocitinib
Therapeutic Area : Dermatology
Study Phase : Phase III
Sponsor : DKSH
Deal Size : Undisclosed
Deal Type : Partnership
Details : The agreement will support both LEO Pharma’s strategy of building a simpler and more competitive organization and pipeline including its lead asset LP0133 (delgocitinib) and DKSH Business Unit Healthcare’s strategic focus of strengthening its regiona...
Brand Name : LP0133
Molecule Type : Small molecule
Upfront Cash : Undisclosed
September 29, 2022
Lead Product(s) : Delgocitinib
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Sponsor : DKSH
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Delgocitinib
Therapeutic Area : Dermatology
Study Phase : Phase III
Sponsor : Japan Tobacco Inc
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Delgocitinib inhibits activation of the JAK-STAT pathway, which plays a key role in the immune system in driving the pathophysiology of chronic inflammatory skin diseases.
Brand Name : LP0133
Molecule Type : Small molecule
Upfront Cash : Not Applicable
May 18, 2021
Lead Product(s) : Delgocitinib
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Sponsor : Japan Tobacco Inc
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Delgocitinib
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : Japan Tobacco Inc
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Delgocitinib inhibits activation of the JAK-STAT pathway, which plays a key role in the immune system in driving the pathophysiology of chronic inflammatory skin diseases. delgocitinib cream demonstrated a statistically significant dose-response relation...
Brand Name : LEO 124249
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 29, 2020
Lead Product(s) : Delgocitinib
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : Japan Tobacco Inc
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Delgocitinib
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : Japan Tobacco Inc
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Delgocitinib inhibits activation of the JAK-STAT pathway, which plays a key role in the immune system in driving the pathophysiology of chronic inflammatory skin diseases.
Brand Name : LEO 124249
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 04, 2020
Lead Product(s) : Delgocitinib
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : Japan Tobacco Inc
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Delgocitinib
Therapeutic Area : Dermatology
Study Phase : Phase III
Sponsor : Japan Tobacco Inc
Deal Size : Undisclosed
Deal Type : Licensing Agreement
JT to market CORECTIM in Japan to treat atopic dermatitis
Details : Under the terms of the agreement on October 2016nbetween JT and Torii, the drugs will be sold exclusively by Torii in Japan, following itsninclusion in the National Health Insurance (NHI) price list.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
January 15, 2020
Lead Product(s) : Delgocitinib
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Sponsor : Japan Tobacco Inc
Deal Size : Undisclosed
Deal Type : Licensing Agreement
LOOKING FOR A SUPPLIER?